Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

>

Phase 1b/2 Study of Voreloxin in Combination with Cytarabine in Relapsed/Refractory AML

Researchers also presented interim data from an ongoing Phase 1b/2 clinical trial testing voreloxin in combination with cytarabine. The Phase 1b/2 trial is designed to evaluate the safety, pharmacokinetics and anti-leukemic activity of escalating doses of voreloxin when administered on days one and four with a fixed dose of cytarabine given either as a continuous infusion (Schedule A) or as a daily IV bolus (Schedule B) for five days.

To date, 45 patients have been treated in Schedule A and preliminary data is available for 38 patients in the dose escalation portion of the study. Nine of these 38 patients have achieved a CR or CRp in voreloxin dose cohorts ranging from 20 to 90 mg/m(2). Complete remissions have been observed in both relapsed and in treatment refractory AML patients. Schedule A has also been generally well tolerated with an acceptable safety profile in this heavily pretreated population. A maximum tolerated dose (MTD) of 80 mg/m(2) of voreloxin was established for Schedule A, and AML patients in first relapse are now being enrolled at the MTD in the Phase 2 portion of this study.

Single agent cytarabine is the current treatment standard for relapsed AML patients dosed across a range of different dose levels administered by either bolus infusion or 24 hour continuous infusion with typical remission rates of approximately 20 percent. Schedule B was recently opened for enrollment with a starting dose of voreloxin at 70 mg/m(2) on days one and four. The first cohort of patients has been fully enrolled in Schedule B.

"Voreloxin has demonstrated anti-leukemic activity when administered in combination with cytarabine," said Judith E. Karp, M.D., Director, Adult Leukemia Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and an in
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has announced ... Global Trends, Estimates and Forecasts, 2012-2018" report to ... Global Electrocardiogram Devices (ECG) sector is projected ... North America accounts for nearly 36% (2015) ... claims approximately 27% (2018). Asia-Pacific ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... , FREMONT, Calif. , March 11 Lorom West, a premier manufacturer of custom cables, wire harnesses, PCB and high quality OEM/ODM products today announced successful certification ... ... ... ...
... March 11 Zimmer Holdings, Inc. (NYSE: ... showcased its recently introduced Continuum Acetabular Cup System ...  The Continuum Cup combines ... Metal™ Technology, Metasul ® Metal-on-Metal technology, BIOLOX ...
Cached Medicine Technology:Lorom West Announces Successful Certification to the ISO 13485: 2003 Quality Management Standard (QMS) for Medical Devices 2Lorom West Announces Successful Certification to the ISO 13485: 2003 Quality Management Standard (QMS) for Medical Devices 3New Hip Implant Provides Personalized Fit 2New Hip Implant Provides Personalized Fit 3New Hip Implant Provides Personalized Fit 4
(Date:12/17/2014)... This prestigious award is given annually ... outstanding and innovative contributions to the physical therapy ... practice physical therapy by the Private Practice Section ... behalf of Performance Physical Therapy, Michelle Collie PT, ... accepted the award at the Private Practice, APTA ...
(Date:12/17/2014)... A group of 127 scientists sent an “open letter” ... a recent statement by the center that was highly critical ... efficacy of all brain exercises. , Signatories to the open ... center’s statement critical of brain exercise companies that overstate their ... case, in a document it had entitled “A Consensus on ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 No ... not been able to eradicate the head louse parasite—a ... hassle for parents. Each year between six and twelve ... Troopers, the Miami-based lice removal treatment company comes to ... non-toxic and environmentally friendly. With its track record of ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Project Veritas ... recently brought videos of MIT economist and Obamacare architect ... author James O’Keefe conducted the interview, which is being ... that there was intentional mislabeling in the Affordable Care ... the bill: A two-hundred-and-fifty billion dollar per year tax ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... diseases, one worrisome phenomenon is when an illness that originated ... known as zoonosis -- is not uncommon and keeps researchers ... animal-borne disease might make inroads into the human population. ... and the culprits in this case were guinea pigs. More ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3
... are developing the first device able to transmit American ... just completing its initial field test by participants in ... "This is the first study of how deaf people ... project leader Eve Riskin, a UW professor of electrical ...
... MONDAY, Aug. 16 (HealthDay News) -- Folks with Internet connections ... folks without access to the Web, a new study shows. ... the old standby, "friends," as the number one way to ... at the American Sociological Association annual meeting in Atlanta. ...
... with cancer progression when abundant inside of tumors also ... feed the tumor outside, a research team led by ... Center reports in the August edition of Cancer ... block production of the protein, the researchers inhibited formation ...
... University have won federal support to develop a genomic test ... by a natural pathogen or one that was grown in ... first from the Defense Threat Reduction Agency -- is designed ... tools they need to quickly determine how to respond to ...
... Mount Sinai School of Medicine have for the first ... vulnerable to rupture using multi-color computed tomography (CT), an ... of cardiovascular disease. The data are published in the ... atherosclerotic plaques are the cause of nearly 70 percent ...
... The Donor Risk Index, which assesses donor characteristics impacting liver ... on a small scale as is suggested from large-scale, national ... to be the major contributor to poor graft survival in ... The goals of the study were to confirm the effect ...
Cached Medicine News:Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3Health News:Web Connection Raises Chances of Romance 2Health News:Web Connection Raises Chances of Romance 3Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 2Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 3Health News:Telltale signs of bioterror 2Health News:Mount Sinai pioneers new cardiac imaging device 2Health News:Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: